Want to see AU:NC6 full AI Analyst Report?
Top Page
Nanollose Ltd.
(Sydney:NC6)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.07
▲(44.00% Upside)
Action:Upgraded
Date:07/09/26
The score is primarily held back by weak financial performance—persistent losses, zero revenue in FY2025, and ongoing negative free cash flow implying funding risk. Technicals are moderately supportive with the stock above major moving averages, but overbought signals and a slightly negative MACD reduce confidence. Valuation provides limited support given the negative P/E and no dividend yield data.
Positive Factors
Sustainable business model
Nanollose’s core technology—microbial cellulose via fermentation—aligns with durable sustainability trends in textiles and materials. This structural market tailwind can support long-term demand and premium positioning versus petrochemical and land‑intensive alternatives if commercial scale and quality are sustained.
Negative Factors
Persistent losses
Chronic unprofitability limits internal capital accumulation and amplifies reliance on external funding. Continued negative margins constrain the company’s ability to scale investment in commercialization and R&D without dilution, creating a durable headwind to value creation unless margins materially improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustainable business model
Nanollose’s core technology—microbial cellulose via fermentation—aligns with durable sustainability trends in textiles and materials. This structural market tailwind can support long-term demand and premium positioning versus petrochemical and land‑intensive alternatives if commercial scale and quality are sustained.
Read all positive factors
Nanollose Ltd. (NC6) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$29.44M
Dividend YieldN/A
Average Volume (3M)138.71K
Price to Earnings (P/E)―
Beta (1Y)-0.02
Revenue Growth-100.00%
EPS Growth2.53%
CountryAU
Employees1
SectorConsumer Cyclical
Sector Strength84
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding408,954,380
10 Day Avg. Volume179,263
30 Day Avg. Volume138,709
Financial Highlights & Ratios
PEG Ratio2.33
Price to Book (P/B)34.86
Price to Sales (P/S)0.00
P/FCF Ratio-12.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nanollose Ltd. Business Overview & Revenue Model
Company Description
Nanollose Limited is an Australian biomaterials enterprise dedicated to the research, development, and commercialization of microbial nanocellulose technology. Its product line features Nullarbor Fibre, an innovative lyocell fibre produced without...
How the Company Makes Money
null...
Nanollose Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
54
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 12.50K | 412.16K | 224.61K | 322.86K |
| Gross Profit | -33.11K | -35.83K | -779.20K | 58.29K | -223.55K | -70.57K |
| EBITDA | -2.41M | -1.59M | -1.10M | -1.16M | -1.51M | -873.73K |
| Net Income | -2.23M | -1.43M | -1.16M | -1.35M | -1.57M | -931.04K |
Balance Sheet | ||||||
| Total Assets | 434.76K | 747.79K | 241.95K | 633.24K | 1.91M | 3.38M |
| Cash, Cash Equivalents and Short-Term Investments | 274.97K | 617.32K | 138.75K | 548.25K | 1.59M | 3.01M |
| Total Debt | 250.21K | 13.09K | 42.53K | 11.52K | 38.09K | 37.88K |
| Total Liabilities | 604.51K | 351.38K | 465.64K | 181.61K | 181.51K | 507.83K |
| Stockholders Equity | -169.75K | 396.41K | -223.69K | 451.63K | 1.73M | 2.87M |
Cash Flow | ||||||
| Free Cash Flow | -1.78M | -1.10M | -900.95K | -1.01M | -1.39M | -1.01M |
| Operating Cash Flow | -1.78M | -1.10M | -900.95K | -1.01M | -1.38M | -935.19K |
| Investing Cash Flow | 0.00 | 0.00 | 15.97K | 0.00 | -5.35K | -272.15K |
| Financing Cash Flow | 1.65M | 1.58M | 475.49K | -26.57K | -32.69K | 3.37M |
Nanollose Ltd. Technical Analysis
Neutral
0.05
Price Trends
0.07
Positive
0.07
Negative
0.06
Positive
Market Momentum
<0.01
Negative
55.61
Neutral
90.18
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NC6, the sentiment is Neutral. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.07, and below the 200-day MA of 0.06, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.61 is Neutral, neither overbought nor oversold. The STOCH value of 90.18 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:NC6.
Nanollose Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
54 Neutral | AU$85.00M | -15.00 | -258.19% | ― | 9.28% | -40.00% | |
48 Neutral | AU$78.23M | -73.33 | -142.30% | ― | -45.25% | 40.54% | |
46 Neutral | AU$29.44M | -9.35 | -1964.93% | ― | -100.00% | 2.53% | |
45 Neutral | AU$68.36M | -0.54 | -131.13% | ― | 2086.71% | -116.20% | |
44 Neutral | AU$6.65M | -1.73 | -29.91% | ― | 82.28% | 13.33% | |
41 Neutral | AU$197.43M | -14.05 | -44.80% | ― | 49.03% | -232.68% |
* Consumer Cyclical Sector Average
AU:NC6
Nanollose Ltd.
0.07
>-0.01
-10.00%
AU:OCC
Orthocell Ltd
0.72
-0.58
-44.62%
AU:TRP
Tissue Repair Ltd
0.11
-0.12
-52.17%
AU:ADO
AnteoTech Ltd
0.02
<0.01
37.50%
AU:AVE
Avecho Biotechnology Limited
0.02
0.01
110.00%
AU:BOT
Botanix Pharmaceuticals Limited
0.03
-0.13
-83.23%
Nanollose Ltd. Corporate Events
Nanollose Seeks ASX Quotation for Additional 40,000 Shares
May 29, 2026
Nanollose Limited has applied for quotation on the ASX of 40,000 new fully paid ordinary shares under its existing ticker NC6. The new securities, issued on 29 May 2026 following the exercise or conversion of existing options or other convertible ...
Nanollose Secures $1.58m via Option Conversions to Advance Microbial Cellulose Facility
May 5, 2026
Nanollose has raised $1.58 million in fresh capital since 1 April 2026 through the conversion of options priced at $0.025 and $0.05, reinforcing investor confidence in its biomaterials strategy. The new funds strengthen the company’s balance...
Nanollose Seeks ASX Quotation for 57.9 Million New Shares
May 5, 2026
Nanollose Limited has applied for quotation on the ASX of 57,950,784 ordinary fully paid shares, with an issue date of 30 April 2026. The application, lodged as an Appendix 2A, reflects the conversion or exercise of existing options or other conve...
Nanollose Seeks ASX Quotation for Additional 75,000 Shares
Apr 30, 2026
Nanollose Ltd. has applied to the ASX for quotation of 75,000 new fully paid ordinary shares, to be issued on 30 April 2026. The relatively small equity issuance, arising from the exercise of options or conversion of other securities, marginally i...
Nanollose Seeks ASX Quotation for 1.39 Million New Shares
Apr 28, 2026
Nanollose Ltd. has applied to the ASX for quotation of 1,393,334 new ordinary fully paid shares, expanding its listed securities under the code NC6. The additional shares result from the exercise or conversion of existing options or other converti...
Nanollose Seeks ASX Quotation for Additional Ordinary Shares
Apr 23, 2026
Nanollose Ltd., listed on the ASX under ticker NC6, has filed an application with the exchange for quotation of additional ordinary fully paid shares, confirming its status as a listed entity expanding its quoted capital base. The company is seeki...
Nanollose Seeks ASX Quotation for 300,000 New Shares
Apr 23, 2026
Nanollose Ltd. has applied for quotation on the ASX of 300,000 new fully paid ordinary shares, to be listed under its existing ticker NC6. The new securities, issued on 23 April 2026 following the conversion of options or other convertible instrum...
Nanollose Advances First Microbial Cellulose Pulp Plant and Streamlines Production Process
Apr 21, 2026
Nanollose has reported substantial progress toward establishing its first dedicated microbial cellulose pulp production facility, a key step in its commercialisation strategy for lyocell-grade fibres. The company has launched a competitive global ...
Nanollose Seeks ASX Quotation for 2.38 Million New Shares
Apr 21, 2026
Nanollose Limited has applied to the ASX for quotation of 2,384,990 new ordinary fully paid shares under its existing ticker NC6. The securities are being issued following the exercise or conversion of options or other convertible securities, mode...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.